Alumis Inc. (ALMS)
NASDAQ: ALMS · Real-Time Price · USD
6.76
-0.30 (-4.25%)
Oct 13, 2026, 11:35 AM EDT - Market open
Alumis Employees
As of June 30, 2026, Alumis had 239 total employees, including 237 full-time and 2 part-time employees. The number of employees increased by 12 or 5.29% compared to the same quarter last year. That makes Alumis the 25,510th largest employer in the world and 3,275th in the United States.
Employees
239
Change
12
Growth
5.29%
Revenue / Employee
$30,954
Profits / Employee
-$1,836,640
Market Cap
874.98M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Jun 30, 2026 | 239 | 12 | 5.29% | 237 | 2 |
| Mar 31, 2026 | 227 | 43 | 23.37% | 225 | 2 |
| Dec 31, 2025 | 224 | 54 | 31.76% | 221 | 3 |
| Sep 30, 2025 | 223 | 76 | 51.70% | 221 | 2 |
| Jun 30, 2025 | 227 | 97 | 74.62% | 225 | 2 |
| Mar 31, 2025 | 184 | 75 | 68.81% | 182 | 2 |
| Dec 31, 2024 | 170 | 61 | 55.96% | 168 | 2 |
| Sep 30, 2024 | 147 | 38 | 34.86% | 145 | 2 |
| Jun 30, 2024 | 130 | - | - | 128 | 2 |
| Mar 31, 2024 | 109 | - | - | 107 | 2 |
| Dec 31, 2023 | 109 | - | - | 107 | 2 |
Related Stocks
| Company Name | Employees |
|---|---|
| Ginkgo Bioworks Holdings | 485 |
| Kura Oncology | 260 |
| Rigel Pharmaceuticals | 174 |
| Monte Rosa Therapeutics | 173 |
| MoonLake Immunotherapeutics | 130 |
| Odyssey Therapeutics | 100 |
| Helus Pharma | 100 |
| Alto Neuroscience | 68 |
ALMS News
- 4 days ago - Alumis announces new envudeucitinib data from ONWARD clinical program - TheFly
- 4 days ago - Alumis Announces New Phase 3 Data Demonstrating Envudeucitinib Rapidly and Durably Improved Psoriasis Burden Across Scalp, Itch, and Quality of Life Measures - GlobeNewsWire
- 4 weeks ago - Alumis Transcript: Morgan Stanley 24th Annual Global Healthcare Conference - Transcripts
- 4 weeks ago - Alumis Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference - Transcripts
- 5 weeks ago - Alumis Transcript: Wells Fargo 21st Annual Healthcare Conference - Transcripts
- 5 weeks ago - Alumis to Participate in Upcoming September Investor Conferences - GlobeNewsWire
- 5 weeks ago - Alumis downgraded to Neutral from Buy at Guggenheim - TheFly
- 5 weeks ago - Alumis rises 10.7% - TheFly